FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to an intranasal pharmaceutical dosage form comprising a dosage unit comprising naloxone or its pharmaceutically acceptable salt at a concentration equivalent to a final concentration of naloxone HCl in indicated dosage unit, in the range between 18 mg of naloxone HCl per 1 ml of liquid and 66 mg of naloxone HCl per 1 ml of the application fluid. Dosage unit contains a volume of 100 mcl of application liquid. Present invention also relates to indicated intranasal pharmaceutical dosage unit for use in the treatment of an opioid overdose and/or at least one of its symptoms.
EFFECT: pharmaceutical dosage unit of the invention exhibits a high bioavailability of naloxone in combination with a rapid onset of action and a relatively long period of action.
15 cl, 16 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2587051C2 |
| COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE | 2017 |
|
RU2769397C2 |
| COMPOSITIONS AND METHOD FOR RELIEVING RESPIRATORY DISTRESS CAUSED BY OPIOID OVERDOSE | 2011 |
|
RU2541159C2 |
| COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | 2017 |
|
RU2767062C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF NALOXONE HYDROCHLORIDE-BASED NASAL SPRAY AND METHOD OF OBTAINING THEREOF | 2013 |
|
RU2572217C2 |
| NEW AND EFFECTIVE MEDICINAL FORMS OF TAPENTADOL | 2009 |
|
RU2673882C1 |
| NEW AND EFFECTIVE DOSAGE FORMS OF TAPENTADOL | 2009 |
|
RU2599846C2 |
| INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | 2012 |
|
RU2692245C2 |
| COMBINATIONS OF AGONIST/ANTAGONIST FOR OPIOID | 1998 |
|
RU2241458C2 |
| METHOD FOR PREVENTION ABUSE WITH OPIOID- -CONTAINING MEDICINAL FORMULATIONS | 1998 |
|
RU2228180C2 |
